Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vidofludimus calcium - Immunic

Next Previous
Drug Profile

Vidofludimus calcium - Immunic

Alternative Names: 4SC-101; IM 90838; IMU 838; SC-12267; VidoCa

Latest Information Update: 30 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator 4SC
  • Developer 4SC; Arizona State University; Immunic; Mayo Clinic
  • Class Amides; Anti-inflammatories; Antivirals; Biphenyl compounds; Carboxylic acids; Cyclopentanes; Fluorobenzenes; Phenyl ethers; Small molecules
  • Mechanism of Action Dihydroorotate dehydrogenase inhibitors; Nuclear receptor subfamily 4 group A member 2 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Multiple sclerosis
  • Phase II/III COVID 2019 infections
  • Phase II Crohn's disease; Post acute COVID 19 syndrome; Ulcerative colitis
  • Discontinued Inflammatory bowel diseases; Primary sclerosing cholangitis; Rheumatoid arthritis; Systemic lupus erythematosus; Transplant rejection

Most Recent Events

  • 24 Jun 2025 Updated efficacy and adverse event data from the phase II EMPhASIS trial in Multiple sclerosis released by Immunic
  • 05 Jun 2025 Phase-III clinical trials in Multiple sclerosis in Greece (PO) (NCT05134441)
  • 05 Jun 2025 Immunic completes enrolment in the ENSURE-1 phase III trial for Multiple sclerosis in Albania, Bulgaria, Colombia, Georgia, Greece, Montenegro, Macedonia, Spain, Ukraine and USA (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top